We are pleased to introduce an Interest Free payment plans for purchases up to $7500 with payment terms up to 24 months through Humm.
Please find below the plans and approval criteria.
Our clients can apply online when they purchase product/s from our online shop scenar.com.au/shop and select Humm as a payment method. This will redirect to the Humm website where an account has to be created and approved. Alternatively, please call us on 02 8011 4217, 0416 974 651 and I will process your application over the phone.
All the world is going online in the move to support their businesses and to find new opportunities. RITM OKB ZAO is also going to use this situation to the greatest and mitigate today’s challenges with the revolutionary virtual expo for the global healthcare industry.
In order to adapt to the new normal, RITM OKB is participating in Omnia Health Live, taking place from 22-26 June 2020, organised by Informa Markets Healthcare, organiser of world-leading healthcare events including Arab Health, Hospitalar, Medlab, FIME, Africa Health, Expomed and many more.
Looking forward to meeting you at our virtual booth.
Irina Ershova is Director and Chief Physician of the Moscow SCENAR Center and a SCENAR therapist with more than 20 years of experience. Spe specializes in therapy, radiology, physiotherapy, reflex therapy and SCENAR therapy.
Q: You were a successful doctor. Why did you switch to SCENAR therapy?
A: When I graduated from Sverdlovsk Medical University, I worked in a major clinical hospital for five years and developed from an intern to head of the admissions department. This was a very good school of life that still helps me a lot. My second specialization was X-ray, but after eleven years as an X-ray, I had health problems. The chief physician of my hospital, Tamara Litvinova, suggested to master the ” new technologies This is how I discovered SCENAR therapy.
Q: When did you first use SCENAR?
A: 1996 during the training seminar organized by RITM OKB. Back then I met Yury Gorfinkel, Alexander Revenko and Yakov Grinberg. These three people had a great impact on my development as a SCENAR therapist. From the beginning I realized how unique this technology is. Same device, same rules, but you can treat different diseases – both acute and chronic! I was obsessed with SCENAR therapy.
Q: And who was your first patient?
A: First I was a patient myself and went through all the recovery phases. My health improved considerably and my choice turned out to be right.
I started learning more about SCENAR technology. In order to better understand the holistic approach to treatment of diseases, I studied reflex therapy and homeopathy. This gave me the opportunity to become a licensed SCENAR therapist. For many years of my SCENAR therapy practice I have treated different cases and different patients. I helped some people avoid disabilities and even saved lives. In any case, I had a trusted assistant named SCENAR!
Q: But who was your very first patient?
A: The very first patients were my family members – my husband, my son and my parents. At the time I lacked a lot of knowledge, but I was firmly convinced from the beginning that the SCENAR therapist is always right that the SCENAR device can’t do any damage and the body can treat itself. I learned this at my first SCENAR therapy training, and this has proven to be right many times during my long practice. My family helped me master the basics of this new specialization, and quickly felt the results of the “magic” treatment.
Q: We are often skeptical about Scenar therapy. Can you comment on this?
A: First of all, the majority of doctors don’t know or understand or don’t understand this technology. They often think that this is regular physical therapy with a variety of contraindications.
Second, SCENAR technology has a different approach to patients and diseases than conventional medicine. The doctors are very conservative and don’t tend to accept anything new and progressive.
Thirdly, there are many unfair offers in this market. You can’t ignore the negative experiences of those who have tried some types of “new” medical technologies and found that their advertising mostly does not match reality.
Finally, there is a lack of medical communication and promotion among doctors and patients.
Q: Can you please tell us about the most interesting case you had?
A: Every single patient is unique. I can talk for hours. Here’s an example: A woman, fifty-year-old, was diagnosed with a band tear by traumatologists. The joint movement was significantly restricted, each movement caused pain up to 10 points (NPRS) and up to 7 points in rest as well as oedema and hematomas. She had already installed the rail and was scheduled for surgery. But she refused and came to seek my advice.
Treatment was performed according to active local complaints algorithm. I treated the direct projection of the complaint area, symmetrical area and segments of the lumbar spine. After the first procedure, the pain had completely disappeared in peace and the pain during movement decreased to 3 points. She could even sit. After the second session the rail was removed. The treatment course included 7 sessions. The pain disappeared completely restored joints. Two weeks after the SCENAR course, the patient had another consultation at the CITO (Central Institute of Traumatology and Orthopaedics). The traumatologists concluded: There is no need for surgery!
However, this is not the end of the story. Soon she had a routine ultrasound examination of the small pelvis (she had a history of a large ovarian cyst that did not grow and was under the supervision of the gynecologist for several years). And the ultrasound showed no cyst! Both the patient and gynecologist couldn’t believe it.
But that’s a fact. In SCENAR technology, it was previously referred to as an unforeseen positive result. In many patients, the discomfort and chronic illnesses that were not at the center of SCENAR therapy disappeared. In the end, all family members of this woman became my patients, and the gynecologist is now the active SCENAR user. This case proves once again that SCENAR therapy is the unique treatment method, especially in the acute phase.
Q: Should SCENAR become a common medical tool like a stethoscope or tonometer?
A: Worldwide SCENAR is positioned as a device for pain therapy. It also has significant anti-inflammatory and reparative effects. In addition, there are situations where conventional treatment has no or only minor effects. For example, decubitus in seriously ill patients. This means the most powerful pain, secondary infections and many other complications. With SCENAR, any doctor can help such patients in no time.
Q: Do you agree that every family should have a SCENAR device?
A: Every time something happens to me or my family, we use SCENAR first. And I always wonder – how do people live without them? This is our all-purpose first aid kit, especially in acute conditions. The most common example is respiratory disease. If you treat the projections of the affected organs, the treatment does not take longer than 1-2 days. No complications, often no medication is needed (our “beloved” paracetamol). Any of my patients know SCENAR can help in any situation, it’s a clinic and first aid in your pocket.
Q: How do you assess the prospects for developing SCENAR therapy?
A: The cholistic medicine that belongs to SCENAR therapy is the future. There is a lot to do to make this method known in general. I think today the main task of RITM OKB is to translate this method into the combined therapy of various diseases. I want to believe that SCENAR therapy will be much widespread in the near future. I hope so!
Dear Friends and Colleagues, thank you for your positive feedback.
We hope that the last webinars were interesting and informative for you. Before moving to the next part of online webinars we would like to make sure that you asked all questions and understood the given material.
On June 4 and June 5 at 7pm Sydney time (12:00 PM, Moscow time) we will have a QA session during which you will have a chance to ask any questions on the past webinars (“Manual Settings of professional SCENAR devices”, “Presets of professional SCENAR devices”, “SCENAR and treatment of respiratory diseases”).
FREE Webinars – Respiratory Diseases (new) and Presets (repeat)
The next topic of the series of free webinars, organised by RITM OKB ZAO is
SCENAR treatment of respiratory diseases
The webinar aims to provide some quick and easy treatment techniques for reducing pain and discomfort caused by respiratory diseases.
The speaker is Boris Kulizshskiy – SCENAR therapist with more than 20 years or experience, physiologist, psychologist, research doctor of RITM OKB ZAO, and scientific referent of DeGAT e.V.
We strongly recommend that all SCENAR Practitioners attend the webinar to upgrade their knowledge. Participants of this webinar can claim 1 CPD towards their Professional Development requirements from SPA.
Additionally, RITM are repeating the Professional devices Presets Webinar for those clients who have missed to attend last month. Please use this opportunity to learn how and when to use the presets in your device. As always, there will be a Q&A session at the end of the webinar and you can ask any questions related to SCENAR.
Presets of professional SCENAR devices (repeat)
Monday (May 25) at 7:00 pm Sydney time (12:00 PM Moscow time)
Tuesday (May 26) at 7:00 pm Sydney time (12:00 PM Moscow time)
SCENAR treatment of respiratory diseases (new!)
Thursday (May 28) at 7:00 pm Sydney time (12:00 PM Moscow time)
Friday (May 29) at 7:00 pm Sydney time (12:00 PM Moscow time)
How to register
The webinars are free and open to everyone. If you already participated in any of our previous webinars, you will receive a link via email.
If it is your first time, please register by emailing to [email protected] and provide the following information:
1. Your name 2. Model of your device (if you have one) 3. How did you hear about SCENAR? 4. Which day are you going to attend?
You will then receive a link to the Zoom webinar.
All webinar attendees will receive a link to download the recorded webinar.
Alternatively, the materials can be accesses in our online training website – https://www.ritmscenar.com.au/. The recordings will be uploaded under WEBINARS sections of the following courses:
In case your account has expired, you can become a member of the SCENAR Practitioners Association (SPA) – https://scenarassociation.org.au/ and all your online trainings will be activated for free for the duration of your membership. Additionally, you will benefit 20% discount on our products.
A recent Randomized Pilot Trial indicates that implementation of RITM SCENAR treatment in conservative pain management of patients with knee osteoarthritis seems to be beneficial to reduce knee pain and improve knee function. Moreover, RITM SCENAR showed a continuing effect and might be an additional treatment modality in particular for patients with severe medical comorbidities who are at high risk for complications in total joint replacement surgery.
Background: Knee osteoarthritis is a major cause of knee pain. Conservative therapy resources are limited due to adverse effects. Therefore, alternative non-invasive therapy approaches to reduce pain medications are gaining importance. The current study analyses if electrical auricular acupuncture (EAA) or low frequency modulated electric current therapy (LFMECT) could support analgesic treatment. Methods: In a randomized pilot trial patients with painful knee OA were treated with EAA (group 1) or LFMECT (group 2) additional to standard pharmacological analgesic treatment. In total 19 female and 10 male patients with a mean age of 59.1 years (standard deviation ± 13.6) and a mean BMI of 28.9 kg/m2 (± 5.2) were included. Patients were randomly assigned to one of the groups stratified for age, gender and BMI. Before starting of the active study period and collecting of the initial data on day 1, all patients received a pharmacological analgesic baseline therapy for one week. At the next study stage patients started their randomly assigned treatment protocol for 42 days and final follow-up was set on day 70. Patients recorded their pain intensity (numerical rating scale; NRS) using a standardized patient diary. The pain free walking time in min was recorded and range of motion was assessed. Results: Rescue medication intake was comparable between both groups on day 42 (p = 0.55) and day 70 (p = 0.35). After the active study period (day 42) pain scores decreased significantly in both groups (group 1 p = 0.02; group 2 p = 0.0006). At follow up median pain scores further decreased in group 1 (p = 0.0002) and remained at a low level in group 2 (p = 0.001). Level of pain decreased in about 50% in both groups and was comparable during the study period. Total mean range of motion (ROM) increased in both groups (group 1 p = 0.0003; group 2 p = 0.02). Group 1 had more improvement of mean total ROM compared to group 2 (p = 0.034). Pain-free walking time increased in both groups and was comparable between both groups (p = 0.31). Any adverse effects due to EAA or LFMECT were not observed. Conclusions: Data of the current study indicates that implementation of EAA or LFMECT seems to be beneficial to reduce knee pain and improve knee function in patients with knee osteoarthritis.
Keywords: knee osteoarthritis, conservative therapy, pharmacological analgesics, electrical auricular acupuncture (EAA), low frequency modulated electric current therapy (LFMECT)Go to:
Knee osteoarthritis (OA) is a major cause of knee pain. Resources for pain reduction without causing adverse effects are limited and are needed for patients who are not suitable for surgery. Therefore, alternative approaches, such as acupuncture or acupressure, are gaining importance. Classical acupuncture points are located on the “meridians” or on the ears as described by Nogier et al. . Auricular acupuncture points are based on the corresponding somatotopic relation of the ear with different anatomical regions . Stimulation of acupuncture points can be achieved by insertion of fine needles or by electrical- or laser stimulation. The analgesic effect of EAA analgesia seems to be related due to activation of descending inhibitory pain control systems, depression of long-lasting pain-induced patterns in the spinal signal transduction, and release of endogenous opioid peptides, [3,4,5,6]. Stimulation of acupuncture points with EAA had shown to influence local blood supply in the corresponding body region .
The P-Stim®™ device (Biegler GmbH, Mauerbach, Austria) was developed to provide continuous EAA for several days. It uses special auricular needles, which are placed on selected acupuncture points, and are connected by wires to a microcontroller fixed behind the ear. It applies a defined periodical electrical stimulation followed by stimulation breaks to prevent tolerance or adaption. In patients with chronic cervical or low back pain electrical auricular acupuncture (EAA) using the P-Stim®™ device showed to be more effective than conventional auricular needle acupuncture [7,8,9].
Another non-invasive treatment modality is low frequency modulated electric current therapy (LFMECT) with the self-controlled energo-neuro adaptive regulation device (SCENAR®™, Enerbalance GMBH, Vienna, Austria) (Figure 1), which is a handheld electrotherapeutic device to stimulate acupuncture-points. The SCENAR®™ devices utilizes innervation of C-fibers in the neural system to trigger a release of neuro-regulative-peptides to stimulate pain relief . In comparison to other electrostimulation systems, the SCENAR®™ is able to measure the patient’s individual response to the electrostimulation and it accordingly modifies the upcoming impulses.
The EAA and LFMECT devices are presented. (A) Low frequency modulated electric current therapy (LFMECT) was performed using the SCENAR®™ device. The body acupuncture-meridians, bladder-meridian and Bachmann-points were stimulated on an outpatient basis. (B) For electrical auricular acupuncture (EAA) the P-Stim®™ device was used. Before insertion of the acupuncture needles, skin resistance was measured with an electrical conductance meter to identify the exact acupuncture points (Shen Men 55, knee 49, and cushion 29). Titan disposable auricular needles were inserted at the dominant side and connected to the P-Stim®™ device. Patients received continuous low-frequency EAA for 96 hours on an outpatient basis.
The number of randomized controlled trials investigating needle acupuncture for knee osteoarthritis (OA) has increased in the last years [11,12]. In contrast limited data about EAA and LFMECT are available. Therefore, the current study analyses if electrostimulation of acupuncture points can support pain management in patients with knee OA.Go to:
2. Material and Methods
The current randomized pilot trial assessed patients with painful knee OA undergoing EAA or LFMECT additional to standard pharmacological analgesic treatment. The study was approved by the Institutional Review Board on the 5 April 2007 (EK 097/2007) and written informed consent was obtained from all participants.
Patients were randomly assigned to two groups (Figure 2). In group 1 patients underwent EAA and in group 2 LFMECT additional to standard pharmacological analgesic treatment. All patients were treated at a specialized outpatient pain centre. Before beginning of their randomly assigned treatment protocol, patients received a standardized baseline oral pharmacological analgesic treatment for one week.
Inclusion criteria were age of 18 years or older, a history of knee pain of at least three months, knee pain on most of the days of the past month, an average pain level of ?3 out of 10 on a numerical rating scale (NRS 0 = no pain, 10 = maximal pain), knee stiffness in the morning of maximal 30 min duration and radiological knee OA (grade >1 according to Kellgren and Lawrence ). Exclusion criteria were pregnancy, neurological or psychiatric disorders, pacemaker, cardiac malformation, valvular transplant (risk of endocarditis), acute infection, chronic infection disease (HIV, hepatitis) and immunosuppression (corticoid therapy). Additionally, patients with contraindications for vagal stimulation (e.g., bronchial asthma) were excluded.
Further exclusion criteria were coagulopathy, contraindication for Metamizol or Tramadol intake, skin disorders (ear or knee) and pre-existing pain medication intake (? grade II world health organization (WHO)).
In total 31 patients were recruited at the outpatient pain centre. Patients were randomly assigned to one of the intervention groups (EAA or LFMECT) stratified for age, gender, and BMI. Randomization was performed as previously reported by Sator-Katzenschalger et al. using computer-generated randomization . Patients were blinded to the treatment protocol of the other study arm. EAA or LFMECT were performed by specialized study nurses and the examiners were blinded for the patient’s treatment protocol.
15 patients were randomized to the EAA group (group 1) and 16 patients to the LFMECT group (group 2). Two female patients in the LFMECT (group 2) were excluded due to incompliance. Finally, 19 female and 10 male patients with a mean age of 59.1 years (± 13.6) and a mean BMI of 28.9 kg/m2 (± 5.2) were included.
Before beginning of their assigned treatment protocol, patients received a pharmacological oral analgesic baseline treatment (Metamizol 1000 mg, 3 times daily and rescue medication with up to six times, 50 mg tramadol per day) for one week. After one-week patients were clinically evaluated and baseline data were collected. In the next study stage, all patients started their assigned treatment protocol (EAA or LFMECT). This time point was set as day 1. The active study period was six weeks (42 days). All patients received EAA or LFMECT on day 1, 7, 14, 21, 28, and 35. All clinical assessments were performed by three fourth year medical students, who were supervised by seven physicians at the outpatient pain center in the midmorning. The active study period ended on day 42 and final follow-up was set on day 70. Patients recorded their required daily rescue medication intake, pain intensity (numerical rating scale; NRS), psychological well-being, quality of sleep, nausea, emesis, and fatigue in a standardized patient diary. Clinical evaluation included knee effusion and active range of motion (ROM). All examiners were trained by an experienced orthopedic trauma surgeon and they trained on several patients with OA not related to the current study. Knee effusion was assessed with the patellar tap test and was rated as positive or negative. ROM was measured according to the neutral zero method with a goniometer using the greater trochanter, lateral femoral epicondyle, fibular head, and lateral malleolus as reference points. All measurements were performed three times and the means were recorded. Moreover, the pain free walking time in min was recorded under standardized conditions. Patients were asked to walk on a flat walking track of 400m length with a consistent walking speed of 3 km/h until they were suffering knee pain.
In group 1 patients received additional to the standardized basic pharmacological analgesic therapy (Metamizol 1000 mg, three times daily and rescue medication with up to six times, 50 mg tramadol per day) electrical auricular acupuncture (EAA) using the P-Stim®™ device (Figure 1). Before insertion of the acupuncture needles, skin resistance was measured with an electrical conductance meter (multipoint selection pen®™, Biegler GmbH, Mauerbach, Austria) to identify the acupuncture points (Shen Men 55, knee 49, and cushion 29). Titan disposable auricular needles (27 gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria) were inserted in the acupuncture points at the dominant side and connected to the P-Stim®™ device. Patients in the auricular acupuncture group (group 1) received continuous low frequency EAA for 96 hours on an outpatient basis. The P-Stim®™ device and acupuncture needles were withdrawn by the patients 96 hours after insertion.
Participants in group 2 had in addition to the standardized basic pharmacological treatment low frequency modulated electric current therapy (LFMECT) using the SCENAR®™ device (Figure 1). It is a handheld electrotherapeutic device with two integrated electrodes. One electrode delivers computer-modulated electrostimulation via the patient’s skin, while the other one monitors the skin impedance constantly, thus providing a biofeedback mechanism. The SCENAR®™ impulse is carried by afferent nerve pathways to the regulatory centers in the brain and triggers a respond signal of the efferent nerves. The LFMECT device SCENAR®™ analyze the nerve response and adapts the next impulse for each patient individually. The pathway of pain relief of this technique utilizes the stimulation of the C-fiber neural system. A sufficiently stimulation of this system triggers the release of neuro-regulative-peptides which results in pain relief, (Ing 2007). In the current study following acupuncture points were stimulated with the SCENAR®™ device: the body acupuncture meridians, bladder meridian, and Bachmann points.
The primary outcome parameter was required daily intake of rescue medication. Comparisons between the two groups were performed using the nonparametric Wilcoxon rank sum test. Secondary outcome parameters were pain (NRS), ROM, and pain-free walking time. Continuous outcome variables are presented by mean (± standard deviation). For variables with skewed distribution the median (quartiles) was used. Due to the skewed distribution log-transformed values of the pain-free walking time were used. Analyses of covariance (ANCOVA) models were used for comparison of the outcome variables pain, ROM and pain-free walking time, between the two intervention groups, including the respective baseline values (day 1) as a covariate. Repeated measures analysis of variance (ANOVA) models were calculated to evaluate the secondary outcome variables pain and psychological well-being, compared to baseline values, additionally including follow-up values (day 70). The nonparametric Wilcoxon signed rank test was used to evaluate changes in the subjective outcome variable sleep, as it was not normally distributed. All statistical tests were two-sided and a p value < 0.05 was considered statistically significant.Go to:
Rescue medication intake was comparable in both groups on day 42 (p = 0.55) and day 70 (p = 0.35) (Table 1 and Figure 3). Pain scores after baseline therapy were comparable between the groups (day 1 in group 1 (6 (Q1 = 3; Q3 = 7)) and group 2 (4 (Q1 = 3; Q3 = 5)). After the active study period (day 42) pain scores decreased significantly in both groups (group 1: 3 (2;5), p = 0.02; group 2: 2 (1;3), p = 0.0006). At follow up median pain scores further decreased in group 1 (median 1.5 (0;3) p = 0.0002) and remained at a low level in group 2 (median 2 (1;3), p = 0.001). Level of pain decreased in both groups in about 50% (Figure 4) and pain scores were comparable during the whole study period (Figure 4).
Comparison of pain intensity measured by numerical rating scale (NRS).
Required daily pharmacological rescue medication intake after baseline therapy, at the end of the active study period and at follow-up of all groups.
56.5 (± 13.4)
61.8 (± 13.7)
29.8 (± 5.6)
Rescue medication after baseline therapy (day 1) *
Rescue medication (day 42) *
Rescue medication (day 70) *
EAA, electrical auricular acupuncture; LFMECT, low frequency modulated electric current therapy; Variables are presented by mean (± standard deviation) or median (quartiles 25%–75%); * Median number of 50 mg tramadol intakes per day.
On day 1 mean total ROM was in group 1 105° (± 21) and in group 2 101° (± 28). At the end of the treatment mean total ROM increased in both groups (group 1 126° (± 12), p = 0.0003; group 2 114° (± 19), p = 0.02). Group 1 showed more improvement of mean total ROM compared to group 2 (p = 0.034). The mean extension lag in group 1 decreased from 6° (± 10) at baseline assessment to 2° (± 4) at the end of treatment. In group 2 the mean extension lag improved from 3° (± 5) to 1° (± 3).
Pain-free walking time was after baseline therapy 30 min (10;45) in group 1 and 20 min (10;60) in group 2. At the end of the active study phase an increased pain-free walking time was recorded in both groups (group 1, 90 min (60;180), p = 0.0001, group 2 60 min (40;100), p = 0.0006). The improvement of the pain-free walking time was comparable (p = 0.31). Effusion was extremely rarely observed despite an increasing activity level during the study period.
Psychological well-being and sleep were analyzed together as the results were comparable. Psychological well-being improved in both groups during the active study period (p = 0.005) and improved further at final follow-up compared to baseline values (p < 0.0001). Also, an improvement of psychological well-being between the end of the active study period and final follow-up (p = 0.02) was observed in both groups (Table 2).
Pain scores, psychological well-being and quality of sleep after baseline therapy, at the end of the active study period and at follow-up.
Pain score after baseline therapy (day 1)
Pain score end of treatment (day 42)
Pain score at follow-up (day 70)
Psychological well-being after baseline therapy (day 1)
Psychological well-being at the end of therapy (day 42)
Psychological well-being at follow-up (day 70)
Quality of sleep after baseline therapy (day 1)
Quality of sleep at the end of treatment (day 42)
Quality of sleep at follow-up (day 70)
Variables are presented by median (quartiles 25%–75%).
Quality of sleep was comparable between the beginning and the end of the active study period (p = 0.07). Quality of sleep improved in both groups at final follow-up (p = 0.03) (Table 2).
Occurrence of nausea, emesis, and fatigue was caused mainly due to side effects of tramadol intake and was were analyzed together. Nausea was rarely reported during baseline therapy and occurrence of emesis was not recorded during the whole study period. Fatigue values were decreased during the study period and stayed at a low level at final follow-up.
Adverse effects of EAA such as occurrence of auricular hematoma, local infection, or hypotension did not occur. Also, patients undergoing LFMECT did not report any adverse events.Go to:
Implementation of EAA or LMFECT seems to be beneficial to support pain management in knee OA. Data of the current study indicates that these therapy modalities seems to be beneficial to reduce knee pain and improve knee function in patients with knee OA.
Acupuncture for patients with OA or chronic pain seems to be a valuable additional treatment option for pain reduction and functional improvement [14,15,16]. The aging population and increasing incidence of obesity are increasing the risk of knee osteoarthritis . Therefore, conservative therapy modalities are gaining in importance, in particular for patients who are at high risk for perioperative and postoperative complications in total joint replacement surgery. For these patients EAA and LFMECT might be encouraging treatment options. Moreover, in these patients a decreased amount of pharmacological analgesics would be beneficial.
Mavrommatis et al.  compared in a randomized, placebo-controlled trial three different treatment protocols for patients with knee OA. Group 1 additionally underwent pharmacological treatment acupuncture, group 2 sham acupuncture (needling at defined non-acupuncture points), and group 3 had stand-alone pharmacological treatment. They revealed that acupuncture, as an add-on therapy was more effective than sham acupuncture and stand-alone pharmacological treatment. Scharf et al.  performed a three-armed randomized investigation comparing traditional Chinese acupuncture, sham acupuncture, and pharmacological analgesics in patients with chronic pain due to knee OA. In comparison to the study by Mavrommatis et al. , Scharf et al.  revealed that acupuncture and also sham acupuncture resulted in a higher clinical improvement compared to pharmacological analgesics. They suggest that these results might be a result of an increased patient attention by the practitioners or a placebo effect due to acupuncture and needling. Hinman et al. , conducted a prospective randomized study and reported modest improvement in pain comparing acupuncture versus non-acupuncture in patients with chronic knee pain due to osteoarthritis. In contrast to the current study, acupuncture was performed as a stand-alone therapy, whereas in the current study EAA and LFMECT were used as an add-on therapy additionally to standard pharmacological treatment. The current study revealed that EAA and LFMECT support the reduction of required pharmacological medications. Moreover, data of the current study indicates that EAA and LFMECT have a continuing beneficial effect on psychological well-being and a reduction of pain beyond the active study period.
Nonetheless following limitations of the current study have to be considered: (1) Only a limited number of patients were analyzed, however, patients were prospectively and randomly allocated to the intervention groups. (2) An intra- and interobserver reliability analysis of evaluation of knee effusion and ROM measurement was not performed prior the study. (3) Patients were not controlled for level of physical activity, daily working hours or weight changes. (4) The pain free walking time test is not validated for knee osteoarthritis in the literature, however all measurement in the current study were performed under standardized, controlled and reproducible conditions. (5) A control group only receiving pharmacological analgesic treatment was not included. Further randomized trials comparing EAA and LFMECT with patients receiving stand-alone pharmacological analgesic treatment are needed.Go to:
The current study indicates that implementation of EAA and LFMECT in conservative pain management of patients with knee osteoarthritis seems to be beneficial to reduce knee pain and improve knee function. Moreover, EAA and LFMECT showed a continuing effect and might be an additional treatment modality in particular for patients with severe medical comorbidities who are at high risk for complications in total joint replacement surgery.Go to:
The authors thank Martina Reichhart and Özkan Özdemir for their support in the initial phase of the study.Go to:
Conceptualization: I.K.-M. and S.S.-K.; formal analysis: I.K.-M., A.K., M.P., M.K., and S.S.-K.; investigation: I.K.-M., J.S., M.P., R.S., R.K., P.M., M.K., and S.S.-K.; methodology: I.K.-M., A.K., and S.S.-K.; project administration: I.K.-M., M.P., M.K., and S.S.-K.; resources: I.K.-M., S.H., and S.S.-K.; supervision: I.K.-M., S.H., and S.S.-K.; validation: I.K.-M., A.K., J.S., R.S., R.K., P.M., M.K., and S.S.-K.; visualization: I.K.-M., A.K., J.S., M.P., R.S., R.K., P.M., and M.K.; and S.S.K.; writing—original draft: I.K.-M., A.K., M.K., and S.S.-K.; writing—review and editing: J.S., M.P., R.S., R.K., P.M., and S.H.Go to:
Conflicts of Interest
The authors declare no conflict of interest.Go to:
1. Nogier P. Face to face with auriculotherapy. Acupunct. Electro-Ther. Res. 1983;8:99–100. [PubMed] [Google Scholar]2. Oleson T., Kroening R. A comparison of Chinese and Nogier acupuncture points. Am. J. Acupuncture. 1983;11:205–223. [Google Scholar]3. Willer J.C., Roby A., Le Bars D. Psychophysical and electrophysiological approaches to the pain-relieving effects of heterotopic nociceptive stimuli. Brain. 1984;107:1095–1112. doi: 10.1093/brain/107.4.1095. [PubMed] [CrossRef] [Google Scholar]4. Sandkuhler J. The organization and function of endogenous antinociceptive systems. Prog. Neurobiol. 1996;50:49–81. doi: 10.1016/0301-0082(96)00031-7. [PubMed] [CrossRef] [Google Scholar]5. Mayer D.J. Biological mechanisms of acupuncture. Prog. Brain Res. 2000;122:457–477. [PubMed] [Google Scholar]6. Audette J.F., Ryan A.H. The role of acupuncture in pain management. Phys. Med. Rehabil. Clin. N. Am. 2004;15:749–772. doi: 10.1016/j.pmr.2004.03.009. [PubMed] [CrossRef] [Google Scholar]7. Szeles J.C., Litscher G. Objectivation of cerebral effects with a new continuous electrical auricular stimulation technique for pain management. Neurol. Res. 2004;26:797–800. doi: 10.1179/016164104225016100. [PubMed] [CrossRef] [Google Scholar]8. Sator-Katzenschlager S.M., Szeles J.C., Scharbert G., Michalek-Sauberer A., Kober A., Heinze G., Kozek-Langenecker S.A. Electrical stimulation of auricular acupuncture points is more effective than conventional manual auricular acupuncture in chronic cervical pain: A pilot study. Anesth. Analg. 2003;97:1469–1473. doi: 10.1213/01.ANE.0000082246.67897.0B. [PubMed] [CrossRef] [Google Scholar]9. Sator-Katzenschlager S.M., Scharbert G., Kozek-Langenecker S.A., Szeles J.C., Finster G., Schiesser A.W., Heinze G., Kress H.G. The short- and long-term benefit in chronic low back pain through adjuvant electrical versus manual auricular acupuncture. Anesth. Analg. 2004;98:1359–1364. doi: 10.1213/01.ANE.0000107941.16173.F7. [PubMed] [CrossRef] [Google Scholar]10. Ing M.R. The use of electronic biofeedback for the management of post-herpetic neuralgia–a report of 3 cases. Hawaii Med. J. 2007;66:234. [PubMed] [Google Scholar]11. Hinman R.S., McCrory P., Pirotta M., Relf I., Crossley K.M., Reddy P., Forbes A., Harris A., Metcalf B.R., Kyriakides M., et al. Efficacy of acupuncture for chronic knee pain: protocol for a randomised controlled trial using a Zelen design. BMC Complement. Altern. Med. 2012;12:161. doi: 10.1186/1472-6882-12-161. [PMC free article] [PubMed] [CrossRef] [Google Scholar]12. Chen L.X., Mao J.J., Fernandes S., Galantino M.L., Guo W., Lariccia P., Teal V.L., Bowman M.A., Schumacher H.R., Farrar J.T. Integrating acupuncture with exercise-based physical therapy for knee osteoarthritis: A randomized controlled trial. J. Clin. Rheumatol. 2013;19:308–316. doi: 10.1097/RHU.0b013e3182a21848. [PMC free article] [PubMed] [CrossRef] [Google Scholar]13. Kellgren J.H., Lawrence J.S. Radiological assessment of osteo-arthrosis. Ann. Rheum. Dis. 1957;16:494–502. doi: 10.1136/ard.16.4.494. [PMC free article] [PubMed] [CrossRef] [Google Scholar]14. Berman B.M., Lao L., Langenberg P., Lee W.L., Gilpin A.M., Hochberg M.C. Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee: A randomized, controlled trial. Ann. Intern. Med. 2004;141:901–910. doi: 10.7326/0003-4819-141-12-200412210-00006. [PubMed] [CrossRef] [Google Scholar]15. White A., Foster N.E., Cummings M., Barlas P. Acupuncture treatment for chronic knee pain: A systematic review. Rheumatology (Oxford) 2007;46:384–390. doi: 10.1093/rheumatology/kel413. [PubMed] [CrossRef] [Google Scholar]16. Manyanga T., Froese M., Zarychanski R., Abou-Setta A., Friesen C., Tennenhouse M., Shay B.L. Pain management with acupuncture in osteoarthritis: A systematic review and meta-analysis. BMC Complement. Altern. Med. 2014;14:312. doi: 10.1186/1472-6882-14-312. [PMC free article] [PubMed] [CrossRef] [Google Scholar]17. Murphy L., Schwartz T.A., Helmick C.G., Renner J.B., Tudor G., Koch G., Dragomir A., Kalsbeek W.D., Luta G., Jordan J.M. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008;59:1207–1213. doi: 10.1002/art.24021. [PMC free article] [PubMed] [CrossRef] [Google Scholar]18. Mavrommatis C.I., Argyra E., Vadalouka A., Vasilakos D.G. Acupuncture as an adjunctive therapy to pharmacological treatment in patients with chronic pain due to osteoarthritis of the knee: A 3-armed, randomized, placebo-controlled trial. Pain. 2012;153:1720–1726. doi: 10.1016/j.pain.2012.05.005. [PubMed] [CrossRef] [Google Scholar]19. Scharf H.P., Mansmann U., Streitberger K., Witte S., Krämer J., Maier C., Trampisch H.J., Victor N. Acupuncture and knee osteoarthritis: A three-armed randomized trial. Ann. Intern. Med. 2006;145:12–20. doi: 10.7326/0003-4819-145-1-200607040-00005. [PubMed] [CrossRef] [Google Scholar]20. Hinman R.S., McCrory P., Pirotta M., Relf I., Forbes A., Crossley K.M., Williamson E., Kyriakides M., Novy K., Metcalf B.R., et al. Acupuncture for chronic knee pain: A randomized clinical trial. JAMA. 2014;312:1313–1322. doi: 10.1001/jama.2014.12660. [PubMed] [CrossRef] [Google Scholar]
Articles from Journal of Clinical Medicine are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)
RITM OKB ZAO has been developing and manufacturing high-end medical equipment for 40 years of its business.
Our main invention was the SCENAR device that now helps people all over the world.
Since the very first SCENAR was developed, RITM OKB ZAO have been carrying out R&D work to continuously develop, research and update the technology. High efficiency and safety of the devices are approved by numerous tests, clinical studies, national and international standards.
The initial successful researches were carried out back in 1986 by the leading institutes of the Soviet Union (Central Research Institute of Traumatology and Orthopedics named after N.N. Priorov and Research Institute of Hominal Physiology named after P.K. Anokhin). At the same time RITM OKB registered their first patents, aimed at protection of their intellectual property. The R&D work has never stopped: many clinical studies were conducted by leading Russian institutes (Institute of Neurosurgery named after N.N. Burdenko, Central Research Institute of Pediatrics and Pediatric Surgery, I.M. Sechenov Moscow Medical Academy), and special studies in Rostov Research Institute of Neurocybernetics and Rostov Institute of Biology.
Practising doctors were the first who got wonderful results and realized the advantages of SCENAR over the existing analogues. That accelerated the SCENAR therapy development. The first patents appeared, in which the measurement of the electrode-skin impedance was used to optimize the therapy. The treatment results of practitioners attracted scientists. Our partners from Rostov Research Institute of Oncology patented the “Method of Combined Treatment of Malignant Neoplasms” and the “Method of Treatment of Malignant Neoplasms in Experiment” with the use of SCENAR therapy. Nizhny Novgorod Medical Academy patented the “Method for treatment of external genital endometriosis”, “Method for Treatment of Tuboperitoneal Infertility” and the “Method for Treatment of Urogenital Infections in Pregnancy”. Together with its Rostov partners, RITM OKB ZAO patented the “Method of Treatment of Acute Myocardial Infarction” and the “Method of Treatment of Abstinence Syndrome in Patients with Opium Addiction”. And many other studies and patents.
RITM OKB partners defended dissertations in various fields with the use of SCENAR therapy (treatment of early postinfarction angina, management of the consequences of the stress of various nature, treatment of duodenal ulcers, treatment and prevention of the aggravations of traumatic mandibular fractures, treatment of habitual miscarriage of infectious nature, and many others).
Other works evidenced the production of endorphins, enkephalins, and other neuropeptides in response to SCENAR therapy. The combination of these substances not only regulates the activity of the systems responsible for pain perception but also coordinates the functioning of many other body structures. It was also evidenced that in response to the SCENAR therapy the sanogenesis mechanisms provide for the oxidative stress reduction, a decrease of the lipid peroxidation products level in the blood, restoring the activity of the antioxidant protection ferments, and decrease in the number and severity of inflammation processes.
In the National Institute for Holistic Addiction Studies (NIFHAS) Siobhan A. Morse, John J. Giordano, and Arthur Anderson studied the SCENAR application for anti-pain therapy (2010). They showed that SCENAR has great potential in combined pain treatment, including chronic pain.
In 2019 a study was carried out at the Bundang Medical Center Department of Neurosurgery at the University of Seongnam (South Korea), which compares the effectiveness of SCENAR and TENS devices. The randomized placebo-controlled study involved 60 patients with neck pain resulting from car accidents. It was evidenced that SCENAR therapy provided for significant neck pain reduction and lower disability rate compared to the group of patients treated with TENS. That allows us to say that SCENAR therapy is more effective than TENS in the treatment of the collar region of the spine.
SCENAR became very popular abroad as the result of the regular training courses on SCENAR therapy carried out by the Russian doctors. These include lectures, workshops on treatment techniques for various disorders and at-home preventive care.
SCENAR changed my life. Over the 22 years, there have been many cases when a patient literally came back to life right before my eyes, started to enjoy his life, and believed that any disease could be treated. Everybody who has SCENAR is confident in his health and uses the device for preventive care, supporting the immune system. This also relates to RITM OKB ZAO staff, of course. They all have one or even several devices, home or professional, in their family. That significantly decreased the number of sick leaves.
We gave SCENAR to the world, gave the opportunity to live without pain, the possibility to control your health. I am proud to lead this company. We keep upgrading our devices and protecting our intellectual property. RITM OKB studies showed the advantages of using dry electrodes, which led to the development of special therapy techniques used in cosmetology. We keep developing the techniques based on the physical reactions of the body to SCENAR influence (electrode stickiness, change of the skin colour, change of the sound tone). Together with our foreign partners, we continue to gain experience in using SCENAR in gynecology, cosmetology, anti-viral therapy and other fields.
Currently, we manufacture new device models that are protected by Russian and foreign patents. The special modes that allow automatically adapting the treatment parameters to the particular patient are protected by the United States patent. Some of our know-how (dosing principles, special device tuning, digitalization and visualization of the feedback parameters) are still kept in secret. SCENAR is a unique and distinctive device, which makes it popular among the medical doctors of various specializations in Russia and other countries. Using professional SCENAR devices by medical doctors in combination with conventional treatment methods leads to nearly unbelievable results. We are confidently looking to the future and going to surprise and please the world over and over again.
Congratulations RITM OKB ZAO!
Wishing you many more years of unparallel success and unrivaled services. Happy anniversary! May this journey of success continue in the coming years.
Interview with Yury Perfiliev for the 40th anniversary journal of RITM OKB ZAO.
Dr. D. med Yury Perfiliev pediatrician, candidate of medicine, extraordinary professor of the Rostov State Medical University (Russia).
Dr. D. Perfiliev has been working with SCENAR for 15 years. According to his observations, the use of SCENAR in medical practice leads to positive results in the treatment of various pathological conditions, which also relate to children.
Q: Why did you start SCENAR therapy? How did it affect you?
A: I am a doctor who grew up according to the principles of the classic Soviet healthcare system. When I first heard about some kind of miracle device, I was quite ironic but remembered the idea. Back then I worked in Africa. When I returned to Russia, one of my friends told me that her daughter treated her patients with a fantastic machine, which made me doubt even more about the amazing possibilities of a small plastic box. But then my intern showed me the analgesic effect of SCENAR treatment. Now I was really interested. I participated in a short SCENAR therapy training and noted that in my hands I hold the device that offers therapeutic influence. Soon I attended a SCENAR therapy conference where I met my student friend, doctor Alexander Tarakanov. Turns out he had been carried away by this technology for a long time. I was also introduced to Jakov Grinberg, who was then Director General of RITM OKB ZAO. At this point I started SCENAR therapy.
Q: They are a pediatrician. How many children have you treated with SCENAR? Can you please tell us the most interesting cases?
A: It’s hard to determine the amount. In addition, I can say that in some cases, the positive effect was achieved by using SCENAR as an independent treatment. In other cases we used the combined treatment because SCENAR works well with other treatment methods to improve their therapeutic effects. I remember a teenager with a full grown gastroesophageal reflux disease (a chronic pathology resulting from gastrointestinal sphinal sphagitis) that caused severe esophagitis (inflammation of the esophagus), multiple stomach erosion and so-called “kissing” (double) pylorus I’m sorry. His condition was documented and recorded on video and made a big impression on other doctors. But they were even more impressed when I showed them the results of a 10 day SCENAR treatment course. There were almost no remaining signs of esophagitis, smooth stomach mucosa, heart rosette formation and thin, barely perceptible ulcer scars.
Later we conducted studies in the Gastroenterology Department to treat other intestinal diseases with SCENAR that showed positive results.
Q: What is SCENAR’s place in modern medicine and where do you think it really belongs?
A: In my opinion, SCENAR occupies an inappropriately insignificant place in modern medicine. This can be explained by the way modern doctors are educated. To be honest, most clinical recommendations nowadays are based only on the use of pharmacology.
How does it usually work? A doctor prescribes the medication. A patient takes them. If there is no positive effect, the doctor will give some other pills. In SCENAR therapy you have to think you have to create individual treatment algorithms, put in some time and effort, sometimes without 100 % guaranteed results. This is because SCENAR therapy is an individualized method of treatment. Every patient is unique. The peculiarities of his body are not always clear from the first session. Sometimes the treatment comes with aggravation, in many cases there must even be aggravated, but the patient may not understand this and rejects treatment.
Despite all the difficulties, SCENAR technology has the future, and I’ll tell you why. Every year we can observe how quickly the body no longer reacts to many medications, especially antibiotics. And soon the alternative (non-medicinal) treatment methods based on knowledge of physiological and pathophysiological processes will come to the forefront. This is the time when SCENAR will take its true place in modern medicine.
And at the moment SCENAR needs more advertising and the involvement of more doctors from different fields in this technology.
Q: There’s a joke: When a cold is treated, a patient recovers in a week if not treated – in seven days. Is SCENAR effective in treating acute respiratory or cold diseases viral infections?
A: The course of the disease depends on the pathogen, level of contamination and immunity of the child. Now we are seeing increasingly lengthy rhinitis accompanied by various complications. In order to prevent such cases, the combined approach is required, including non-medicinal treatment methods. The effectiveness of SCENAR in such diseases is undeniable.
Q: Should SCENAR become a common medical instrument like stethoscope or tonometer?
A: That would be right. Wherever I go, I always have my phonendoscope, auriscope and SCENAR with me. Sometimes a doctor’s help is urgently needed. Phonendoscope and auriscope are the devices for diagnosis, and SCENAR is for treatment. I’ve had many cases where SCENAR helped me in critical situations.
Q: How do you judge the prospects for developing SCENAR therapy in your country and worldwide?
A: It’s not an easy question to answer. Anything used to treat people should have a high level of evidence. This means serious clinical trials: randomized, double blind, multi-centric. This is quite difficult because patients have some very specific feelings during SCENAR therapy. However, this means that we need to look for new approaches to investigate the evidence of the method and incorporate SCENAR into general practice.
Q: Do you agree that every family should have at least one SCENAR home device?
A: Well, I can say all my kids have SCENAR devices as a gift from me, and they saw their effectiveness with their own eyes as they treated the bruises, wounds and sprains of their own children.
The leaders of the Soviet Union space program took an interest in RITM OKB ZAO in 1984. When the Soviet Union decided to send its cosmonauts to the Earth’s orbit for longer periods, it became clear that it is necessary to equip them with some sort of a universal aid that can help against any diseases that might occur. The government started to search for an enterprise that is able to develop a complex for testing, evaluating, training, and psychological relief for the cosmonauts. The officials highly appreciated the qualification of our engineers and their new developments in the sphere of medical technology, so the choice was made in favour of “RITM” Special Design Office.
In this letter, the Cosmonaut Training Center (CTC) asks to develop devices that can stimulate the acupuncture points in order to use them to provide medical and biological support of the cosmonaut training process. The letter was sent to the Taganrog Institute of Radiotechnology (TRTI) and then forwarded to OKB, as the actual contractor. That letter shows the interest of CTC in RITM OKB ZAO developments.
The implementation of this project involved serious scientific potential, taking into account the previous studies carried out in the University of Tartu (Estonia) and the Research Institute of Neurocybernetics (Rostov-on-Don) and with the participation of the specialists from Kyiv and Kharkiv. The engineers of RITM OKB implemented the system with biofeedback. (Photo 2)
During the development of the project RITM OKB ZAO was visited by the high-ranked specialists and engineers, including cosmonauts, for whom the room project was created. The photo shows RITM OKB ZAO director Vladislav (on the left), the rector of Taganrog Institute of Radiotechnology Nikolai Malyshev, the Chief Engineer of RITM OKB ZAO Rudolf Kruykov (in the background), and the Soviet cosmonaut, twice Hero of the Soviet Union and Companion of the Order of Lenin Yury Malyshev (in the center).
This project proved the high level of professionalism of RITM OKB ZAO’s staff and the ability of RITM to solve complex modern problems. That allowed the company to implement such modern developments as INTENS, Stabilan, Myokom, and, of course, SCENAR.
However, it happened so that SCENAR was not used in the space back then. It was necessary to work out a few additional requirements, including installing the protection against water. But the financing was stopped because of the Perestroika. The space race was over and the group of engineers had to finish their developments for the space industry.
Later on, the result of this development was introduced to the Russian medical device market. In 1995-1996 first SCENAR therapists started to treat their patients using the new technology.